Overview

Pilot BA Study of New LY03005 vs Pristiq

Status:
Completed

Trial end date:
2016-12-28

Target enrollment:

Participant gender:

Summary

The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.

Phase:

Phase 1

Details

Lead Sponsor:

Luye Pharma Group Ltd.

Treatments:

Desvenlafaxine Succinate